Hunt S A, Rider A K, Stinson E B, Griepp R B, Schroeder J S, Harrison D C, Shumway N E
Circulation. 1976 Dec;54(6 Suppl):III56-60.
The current status of the human cardiac transplant experience at Stanford University Medical Center is presented in order to reassess its role in the treatment of end-stage cardiac disease. Of 109 patients undergoing transplantation at Stanford between January 1968 and August 1976, 44 were still alive as of August 1, 1976. The overall 1- and 2-year survival rates for the series are 52% and 43%, respectively. Sixty-nine patients have survived more than 3 months, and their overall 1- and 2-year survival rates are 80% and 66%, respectively. Of the 3-month survivors, 62 (90%) returned to functional Class I New York Heart Association cardiac status and most of these returned to their pre-illness activities. Of 40 patients selected for transplantation for whom a donor did not become available, 38 were dead in less than 6 months. Complications related to immunosuppression with steroids are currently the major barrier to longer survival and improved rehabilitation postransplantation. On the basis of these data we conclude that cardiac transplantation not only prolongs survival, but can return carefully selected recipients to an active life.
本文介绍了斯坦福大学医学中心人体心脏移植的现状，以便重新评估其在终末期心脏病治疗中的作用。1968年1月至1976年8月期间，斯坦福大学有109例患者接受了心脏移植，截至1976年8月1日，其中44例仍存活。该系列患者的1年和2年总生存率分别为52%和43%。69例患者存活超过3个月，他们的1年和2年总生存率分别为80%和66%。在存活超过3个月的患者中，62例（90%）恢复到纽约心脏协会心功能I级，其中大多数恢复了病前的活动。在40例被选定进行移植但未获得供体的患者中，38例在不到6个月内死亡。目前，与类固醇免疫抑制相关的并发症是移植后延长生存期和改善康复的主要障碍。基于这些数据，我们得出结论，心脏移植不仅能延长生存期，还能使经过精心挑选的受者恢复积极的生活。
